Savara Inc Reports Q2 Earnings Amid FDA Review Extension

Savara Inc is scheduled to report its second-quarter earnings on Thursday. Financial analysts expect the clinical-stage biotech company to report a loss of $0.145 per share. Because the company currently generates no revenue, investors are closely monitoring its cash position, which stands at approximately $203 million and is expected to provide a runway into the second half of 2027.

The company is preparing for the commercial launch of molgramostim, branded as MOLBREEVI, a Phase 3 candidate designed to treat autoimmune pulmonary alveolar proteinosis. This rare respiratory disease represents the primary focus of the company's current clinical pipeline.

The Food and Drug Administration extended the review period for molgramostim to November 22, 2026. This extension followed a major amendment to the information responses provided by the company. The agency stated that the extension does not stem from concerns regarding the safety, efficacy, or manufacturing of the drug.